Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  • Petri Bono
  • Christophe Massard
  • Katriina J Peltola
  • Analía Azaro
  • Antoine Italiano
  • Rebecca S Kristeleit
  • Giuseppe Curigliano
  • Ulrik Lassen
  • Hendrik-Tobias Arkenau
  • Pasi Hakulinen
  • Chris Garratt
  • Tarja Ikonen
  • Mika V J Mustonen
  • Jordi A Rodon
Vis graf over relationer

BACKGROUND: Genetic alterations in fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) signalling are observed in various tumours. We report a first-in-human phase I/IIa trial evaluating tolerability, pharmacokinetics and preliminary antitumour activity of ODM-203, a novel FGFR and VEGFR inhibitor.

METHODS: Open-label, non-randomised, multicentre, phase I/IIa dose escalation and expansion study in patients with advanced or metastatic solid tumours.

RESULTS: Overall, 84 patients received treatment; optimal tablet dose was found to be 400 mg/day with food. All patients experienced at least one adverse event; the majority (89.2%) were grade 1 or 2% and 70.4% were considered treatment related. The most commonly reported events were bilirubin increase-related events (75%) and diarrhoea (50%).Overall response rate was 9.2% and median progression-free survival was 16.1 and 12.4 weeks for patients with aberrant or non-aberrant FGFR tumours. Median time on treatment was 10.1 weeks for all patients and 14.5 weeks for patients who received 400 mg tablets.

CONCLUSION: This study suggests ODM-203 400 mg/day results in sufficient plasma concentrations and acceptable tolerability in most patients. Preliminary signs of therapeutic activity of ODM-203 in patients with solid tumours was observed.


TidsskriftESMO Open
Udgave nummer6
StatusUdgivet - dec. 2020

Bibliografisk note

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

ID: 61506747